User Tools

Site Tools


iich

benign raised idiopathic intracranial hypertension

Introduction

  • aka pseudotumor cerebri
  • aka idiopathic intracranial hypertension (IICH)
  • a cause of chronic headache

Epidemiology

  • increasingly common

Aetiology / risk factors

  • most commonly occurs in overweight young women
  • medications such as fluoroquinolones and tetracyclines; and vitamin A analogues such as isotretinoin (Roaccutane)

Clinical features

  • chronic headaches
    • can be migraine-like and often occurs daily
    • headache may be worse on waking and worse with Valsavre type events such as coughing
  • may have:
    • visual impairment
      • may be transient upon standing or bending
      • may have reduced peripheral vision
      • may have blurred vision with loss of acuity and colour sensitivity
    • pulsatile tinnitus worse on lying down
  • may have papilloedema
  • may have horizontal diplopia secondary to abducens nerve palsy
  • may have dizziness
  • some have upper cervical or radicular pain
  • have double the normal cardiovascular risk, independent of obesity1)
  • some may develop thing of skull bone resulting in a CSF leak causing severe postural headaches

Radiographic features on CT brain

  • slit-like ventricles
  • other radiologic features that are suggestive of this cause2):
    • optic nerve sheath distension
    • posterior globe flattening
    • optic nerve tortuosity in vertical or horizontal planes
    • papilledema/optic nerve head protrusion
    • optic nerve head enhancement
    • Meckel cave enlargement
    • arachnoid pits (aberrant arachnoid granulations) / small meningoceles, typically within the temporal bone and sphenoid wing
    • enlarged oculomotor cistern
    • prominent perivascular spaces
    • transverse sinus stenosis
    • acquired cerebellar tonsillar ectopia
    • increased subcutaneous fat thickness in the scalp and neck (a slim patient is unlikely to develop idiopathic intracranial hypertension)

Diagnosis

  • confirmed with raised LP opening pressures > 25cm CSF (grey zone is 20-25cm CSF)3)

DDx of raised ICP

Mx

  • any patient with suspected IICH and acute or rapidly declining visual acuity or visual fields needs urgent ophthalmology and neurosurgery review to prevent irreversible blindness.
  • if papilloedema present:
    • emergent MRI, CT brain +/- CT venography
    • neurology consult
    • if CT brain / venography normal then confirm Dx by measuring CSF opening pressure via lumbar puncture (LP) manometry
  • acetazolamide
    • inhibits carbonic anhydrase and therefore reduces CSF production
    • dosage is 250 mg twice a day, titrated according to benefits and tolerability to a maximum of 4 g per day
    • possible side effects, including diarrhoea, vomiting, low mood, paraesthesia, renal stones and teratogenicity.
    • often poorly tolerated and patients are frequently switched to topiramate
  • topiramate
    • inhibits carbonic anhydrase and has the additional benefits of appetite suppression and migraine prevention although there is no randomised evidence of efficacy in IIH
    • starting dose of 25 mg once daily and increased by 25 mg every couple of weeks until achieving a maintenance dose of 50 mg twice a day
    • topiramate is teratogenic (3% risk of major malformations) and should be avoided in pregnancy and it reduces the effectiveness of the combined oral contraceptive pill (OCP)
    • rarely it can cause acute glaucoma and renal stones
    • are being trialled in IIH as they reduce CSF secretion and can have anti-obesity effects
  • consider migraine prevention medications
  • weight loss
    • even modest weight reduction (5–10% of body weight) can significantly reduce intracranial pressure and improve symptoms4)
  • warned not to take painkillers, especially opiates, on more than 2 or 3 days in a given week
  • regular ophthalmology reviews
  • surgical Mx if medical Mx fails or rapid vision loss
    • male patients, and those with severe papilloedema and reduced visual acuity at presentation, are more likely to fail medical therapy5)
    • V-P shunt
    • optic nerve sheath fenestration
iich.txt · Last modified: 2026/07/30 00:59 by gary1

Donate Powered by PHP Valid HTML5 Valid CSS Driven by DokuWiki